Summary

The global Vaccines For Children market is projected to grow from US$ 37451 million in 2025 to US$ 58209 million by 2032, at a CAGR of 6.5% (2026-2032), driven by critical product segments and diverse end‑use applications.
Vaccines for Children (Pediatric Vaccines) are biological preparations developed, approved, or recommended for use in infants, children, and adolescents to prevent infectious diseases by inducing protective immune responses. These vaccines employ various technologies, including live attenuated pathogens, inactivated microorganisms, purified antigens, recombinant proteins, polysaccharide-protein conjugates, and nucleic acid platforms. Major products target diseases such as diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella, hepatitis, pneumococcal infections, rotavirus, meningococcal disease, influenza, and human papillomavirus infections. Pediatric vaccines are administered through intramuscular or subcutaneous injection, oral delivery, and intranasal routes, depending on the product. They are used in routine childhood immunization, supplementary vaccination, and catch-up immunization programs. Their principal distribution and administration channels include national immunization programs, public healthcare systems, hospitals, community health centers, vaccination clinics, and school-based immunization programs.
Key Findings
The global Vaccines for Children market had an indicative average selling price of approximately USD 11.5 per dose in 2025
Vaccines for Children are essential components of national immunization programs and preventive healthcare systems
Combination pediatric vaccines support protection against multiple diseases while reducing the number of separate injections
Hospitals, community health centers, and vaccination clinics are major administration channels for pediatric vaccines
Pediatric vaccine demand is influenced by immunization coverage, birth cohorts, government procurement, and vaccine technology
Market Trends
The Vaccines for Children industry is undergoing structural changes driven by advances in vaccine technology, expansion of combination formulations, and increasing attention to immunization accessibility. Traditional live attenuated and inactivated vaccines remain fundamental to routine childhood immunization, while conjugate vaccines, recombinant antigen technologies, and newer vaccine platforms are broadening disease prevention capabilities. Combination vaccines have become an important development direction because they can reduce the number of injections, simplify immunization schedules, and improve operational efficiency. Manufacturers are also focusing on improved safety profiles, broader serotype coverage, enhanced thermal stability, and more convenient administration methods. Meanwhile, national immunization strategies are increasingly emphasizing lifetime protection beginning in childhood, including selected adolescent immunization programs. Product innovation is gradually shifting toward broader protection, reliable supply, and improved cost-effectiveness throughout the vaccination process.
Market Dynamics
Drivers
Government-supported immunization programs, continued efforts to improve vaccination coverage, and the introduction of new pediatric vaccine products are important drivers of market demand. Vaccination is a fundamental component of preventive healthcare, and public procurement programs create recurring demand for routine childhood vaccines. Growing availability of pneumococcal conjugate, meningococcal, HPV, and combination vaccines also supports market development, particularly in regions expanding their national immunization schedules. Technological improvements in vaccine production and quality control contribute to supply reliability and product performance.
Restraints
The pediatric vaccine industry faces constraints associated with high research and development costs, lengthy clinical evaluation procedures, stringent regulatory requirements, and complex manufacturing processes. Vaccine production requires validated biological processes, specialized facilities, rigorous quality control, and reliable cold-chain logistics. Public procurement systems can create significant price pressure, especially for products supplied through large-scale national immunization programs. Declining birth rates in certain countries may also limit volume growth in established infant vaccination markets.
Opportunities
Market opportunities are emerging from the expansion of national immunization schedules, increased adoption of higher-valency conjugate vaccines, development of combination vaccines, and improved vaccination access in underserved regions. Pediatric HPV vaccination, meningococcal prevention, and next-generation pneumococcal vaccines represent important areas of product development. Manufacturers may also benefit from developing thermostable formulations, simplified administration methods, and locally manufactured vaccines that improve procurement flexibility. Partnerships involving technology transfer, regional manufacturing, and public health procurement can create additional commercial opportunities.
Challenges
Major challenges include maintaining vaccine safety and manufacturing consistency, managing clinical development risks, meeting different regulatory standards, and ensuring uninterrupted supply. Vaccine hesitancy, misinformation, and unequal healthcare access can affect immunization coverage. Manufacturers must also address antigen supply constraints, production capacity requirements, biological manufacturing variability, and cold-chain distribution risks. Competition between established vaccines and newer products requires companies to demonstrate clinically meaningful benefits, reliable availability, and economic value for healthcare systems.
Industry Chain Analysis
The pediatric vaccine industry chain consists of upstream biological materials and technology suppliers, midstream vaccine developers and manufacturers, and downstream healthcare procurement and vaccination systems. Upstream activities include pathogen strain development, antigen research, cell culture materials, fermentation media, adjuvants, stabilizers, sterile packaging, and specialized bioprocess equipment. Midstream manufacturing involves antigen production, purification, formulation, aseptic filling, quality testing, batch release, and regulatory compliance. These activities require substantial capital investment, validated production facilities, and comprehensive quality management systems.
Downstream distribution mainly involves government immunization programs, public healthcare procurement agencies, hospitals, community health centers, vaccination clinics, and selected private healthcare providers. Value creation depends on vaccine efficacy and safety, manufacturing consistency, disease coverage, regulatory approvals, production scale, and supply reliability. Public procurement vaccines commonly face stronger price constraints, whereas differentiated products with broader antigen coverage or specialized indications may support higher unit prices. Manufacturing scale, product portfolios, and established distribution networks are important factors influencing competitive positioning and profitability.
Segment Insights
The Vaccines for Children market can be segmented by vaccine technology, number of target diseases, and recommended age group. By technology, major categories include live attenuated, inactivated, subunit and recombinant, conjugate, toxoid, and nucleic acid vaccines. Traditional vaccine technologies support established childhood immunization schedules, while conjugate vaccines are particularly important in preventing selected bacterial infections among infants and young children. Recombinant vaccine technologies also contribute to prevention of diseases such as hepatitis B and HPV-related infections.
By number of target diseases, the market includes monovalent vaccines, bivalent and trivalent vaccines, and multivalent vaccines targeting four or more diseases. Combination products such as pentavalent and hexavalent pediatric vaccines can simplify vaccination schedules and improve healthcare delivery efficiency. By age group, demand spans infants aged 0–12 months, toddlers aged over 12–36 months, children aged over 3–12 years, and adolescents aged over 12–17 years. Infant vaccination remains a foundational component of routine immunization demand, while adolescent vaccination creates opportunities for HPV and selected booster vaccines. Important competitive factors include antigen coverage, safety, immunogenicity, dosing schedules, regulatory status, and pricing.
Downstream Market Opportunities
Hospitals and community health centers are important administration channels for pediatric vaccines, particularly within publicly funded routine immunization programs. These institutions require reliable product supply, standardized vaccine presentation, appropriate storage conditions, and compatibility with national immunization schedules. Procurement decisions emphasize vaccine safety, approved indications, cost-effectiveness, delivery reliability, and long-term supplier capabilities. Manufacturers with comprehensive product portfolios and stable supply arrangements are well positioned to support large-scale vaccination programs.
Specialized vaccination clinics and private healthcare facilities create additional opportunities for optional vaccines, higher-valency products, and differentiated combination formulations. School-based immunization programs are particularly relevant to selected adolescent vaccines, including HPV vaccines, in jurisdictions where such delivery systems are established. Expansion of community vaccination infrastructure, digital immunization records, and reminder systems can improve vaccination completion rates. Suppliers can strengthen market access through appropriate packaging, convenient dosing schedules, professional education, and cooperation with public health organizations.
Regional Insights
North America represents an important high-value pediatric vaccine market, supported by established immunization recommendations, advanced healthcare infrastructure, and commercial adoption of differentiated vaccine products. Europe also maintains a mature vaccination market, with significant participation by public procurement agencies and national healthcare systems. Product selection and procurement arrangements vary across countries, creating differences in vaccine pricing and adoption.
Asia-Pacific combines substantial childhood vaccination demand with significant vaccine manufacturing capabilities. China has an extensive domestic vaccine production base and established national immunization programs, while Japan maintains a mature vaccination system and specialized vaccine manufacturing capabilities. India is particularly important in large-scale vaccine manufacturing and global vaccine supply. Southeast Asia presents opportunities associated with expanding immunization coverage and improving healthcare infrastructure. Africa and parts of Latin America remain important markets for vaccination-access initiatives, although procurement budgets, affordability, cold-chain infrastructure, and supply arrangements influence commercial development.
Competitive Landscape Analysis
The global Vaccines for Children industry is characterized by a combination of multinational pharmaceutical companies, large-scale vaccine manufacturers, and specialized regional producers. GSK, Sanofi, Merck & Co. (MSD), and Pfizer maintain established pediatric vaccine portfolios supported by research capabilities, regulatory expertise, manufacturing infrastructure, and international commercialization networks. CSL Limited and AstraZeneca participate in selected pediatric vaccination segments, particularly influenza prevention. Serum Institute of India, Bharat Biotech, Biological E. Limited, and Panacea Biotec contribute to vaccine manufacturing and supply, including products used in childhood immunization programs. In China, China National Biotec Group, Hualan Biological Engineering, Shenzhen Kangtai Biological Products, AIM Vaccine, Sinovac Biotech, Walvax Biotechnology, Beijing Wantai Biological Pharmacy, Zhifei Biological, CanSino Biologics, and other specialized manufacturers form an important domestic vaccine industry. Japanese companies including Takeda Pharmaceutical, KM Biologics, Daiichi Sankyo, and Denka participate in relevant vaccine segments, while SK bioscience, GC Biopharma, LG Chem, and Bio Farma contribute additional regional manufacturing capabilities. Competition is influenced by product differentiation, approved indications, manufacturing scale, vaccine quality, regulatory compliance, government procurement access, and long-term supply reliability.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Vaccines For Children market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Vaccine Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
GSK
Sanofi
Merck & Co. (MSD)
Pfizer
CSL Limited (Seqirus)
AstraZeneca (MedImmune)
China National Biotec Group
Hualan Biological Engineering
Shenzhen Kangtai Biological Products
AIM Vaccine (Hissen)
Serum Institute of India
Bharat Biotech
Biological E. Limited
Panacea Biotec
Takeda Pharmaceutical
KM Biologics
Daiichi Sankyo
Sinovac Biotech
Walvax Biotechnology
Beijing Wantai Biological Pharmacy (Innovax)
Zhifei Biological
CanSino Biologics
Changchun High-Tech Industries
Chengda Biotechnology
Denka Company Limited
SK bioscience
GC Biopharma
LG Chem
Bio Farma
Segment by Vaccine Type
Live Attenuated Vaccines
Inactivated Vaccines
Subunit and Recombinant Vaccines
Conjugate Vaccines
Toxoid Vaccines
Nucleic Acid Vaccines
Others
Segment by Number of Target Diseases
Monovalent Vaccines (1 Disease)
Bivalent and Trivalent Vaccines (2–3 Diseases)
Multivalent Vaccines (≥4 Diseases)
Segment by Recommended Age Group
Infant Vaccines (0–12 Months)
Toddler Vaccines (>12–36 Months)
Childhood Vaccines (>3–12 Years)
Adolescent Vaccines (>12–17 Years)
Segment by Application
Hospitals
Community Health Centers
Vaccination Clinics
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Vaccines For Children study scope, segments the market by Vaccine Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Vaccines For Children: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Vaccine Type
1.2.1 Global Vaccines For Children Market Size by Vaccine Type, 2021 vs 2025 vs 2032
1.2.2 Live Attenuated Vaccines
1.2.3 Inactivated Vaccines
1.2.4 Subunit and Recombinant Vaccines
1.2.5 Conjugate Vaccines
1.2.6 Toxoid Vaccines
1.2.7 Nucleic Acid Vaccines
1.2.8 Others
1.3 Market Segmentation by Number of Target Diseases
1.3.1 Global Vaccines For Children Market Size by Number of Target Diseases, 2021 vs 2025 vs 2032
1.3.2 Monovalent Vaccines (1 Disease)
1.3.3 Bivalent and Trivalent Vaccines (2–3 Diseases)
1.3.4 Multivalent Vaccines (≥4 Diseases)
1.4 Market Segmentation by Recommended Age Group
1.4.1 Global Vaccines For Children Market Size by Recommended Age Group, 2021 vs 2025 vs 2032
1.4.2 Infant Vaccines (0–12 Months)
1.4.3 Toddler Vaccines (>12–36 Months)
1.4.4 Childhood Vaccines (>3–12 Years)
1.4.5 Adolescent Vaccines (>12–17 Years)
1.5 Market Segmentation by Application
1.5.1 Global Vaccines For Children Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospitals
1.5.3 Community Health Centers
1.5.4 Vaccination Clinics
1.5.5 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Vaccines For Children Revenue Estimates and Forecasts (2021-2032)
2.2 Global Vaccines For Children Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Vaccines For Children Sales Estimates and Forecasts (2021-2032)
2.4 Global Vaccines For Children Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Vaccines For Children Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Vaccines For Children Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Live Attenuated Vaccines: Market Share by Key Manufacturers
3.5.2 Inactivated Vaccines: Market Share by Key Manufacturers
3.5.3 Subunit and Recombinant Vaccines: Market Share by Key Manufacturers
3.5.4 Conjugate Vaccines: Market Share by Key Manufacturers
3.5.5 Toxoid Vaccines: Market Share by Key Manufacturers
3.5.6 Nucleic Acid Vaccines: Market Share by Key Manufacturers
3.5.7 Others: Market Share by Key Manufacturers
3.6 Global Vaccines For Children Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Vaccines For Children Sales Performance by Vaccine Type
4.1.1 Global Vaccines For Children Sales Volume by Vaccine Type (2021-2032)
4.1.2 Global Vaccines For Children Revenue by Vaccine Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Vaccine Type (2021-2032)
4.2 Global Vaccines For Children Sales Performance by Number of Target Diseases
4.2.1 Global Vaccines For Children Sales Volume by Number of Target Diseases (2021-2032)
4.2.2 Global Vaccines For Children Revenue by Number of Target Diseases (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Number of Target Diseases (2021-2032)
4.3 Global Vaccines For Children Sales Performance by Recommended Age Group
4.3.1 Global Vaccines For Children Sales Volume by Recommended Age Group (2021-2032)
4.3.2 Global Vaccines For Children Revenue by Recommended Age Group (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Recommended Age Group (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Vaccines For Children Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Vaccines For Children Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Vaccines For Children Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Vaccines For Children Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Vaccines For Children Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Vaccines For Children Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Vaccines For Children Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Vaccines For Children Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Vaccines For Children Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Vaccines For Children Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Vaccines For Children Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Vaccines For Children Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 GSK
11.1.1 GSK Corporation Information
11.1.2 GSK Business Overview
11.1.3 GSK Vaccines For Children Product Models, Descriptions and Specifications
11.1.4 GSK Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 GSK Vaccines For Children Sales by Product in 2025
11.1.6 GSK Vaccines For Children Sales by Application in 2025
11.1.7 GSK Vaccines For Children Sales by Geographic Area in 2025
11.1.8 GSK Vaccines For Children SWOT Analysis
11.1.9 GSK Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Vaccines For Children Product Models, Descriptions and Specifications
11.2.4 Sanofi Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Sanofi Vaccines For Children Sales by Product in 2025
11.2.6 Sanofi Vaccines For Children Sales by Application in 2025
11.2.7 Sanofi Vaccines For Children Sales by Geographic Area in 2025
11.2.8 Sanofi Vaccines For Children SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Merck & Co. (MSD)
11.3.1 Merck & Co. (MSD) Corporation Information
11.3.2 Merck & Co. (MSD) Business Overview
11.3.3 Merck & Co. (MSD) Vaccines For Children Product Models, Descriptions and Specifications
11.3.4 Merck & Co. (MSD) Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Merck & Co. (MSD) Vaccines For Children Sales by Product in 2025
11.3.6 Merck & Co. (MSD) Vaccines For Children Sales by Application in 2025
11.3.7 Merck & Co. (MSD) Vaccines For Children Sales by Geographic Area in 2025
11.3.8 Merck & Co. (MSD) Vaccines For Children SWOT Analysis
11.3.9 Merck & Co. (MSD) Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Vaccines For Children Product Models, Descriptions and Specifications
11.4.4 Pfizer Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 Pfizer Vaccines For Children Sales by Product in 2025
11.4.6 Pfizer Vaccines For Children Sales by Application in 2025
11.4.7 Pfizer Vaccines For Children Sales by Geographic Area in 2025
11.4.8 Pfizer Vaccines For Children SWOT Analysis
11.4.9 Pfizer Recent Developments
11.5 CSL Limited (Seqirus)
11.5.1 CSL Limited (Seqirus) Corporation Information
11.5.2 CSL Limited (Seqirus) Business Overview
11.5.3 CSL Limited (Seqirus) Vaccines For Children Product Models, Descriptions and Specifications
11.5.4 CSL Limited (Seqirus) Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 CSL Limited (Seqirus) Vaccines For Children Sales by Product in 2025
11.5.6 CSL Limited (Seqirus) Vaccines For Children Sales by Application in 2025
11.5.7 CSL Limited (Seqirus) Vaccines For Children Sales by Geographic Area in 2025
11.5.8 CSL Limited (Seqirus) Vaccines For Children SWOT Analysis
11.5.9 CSL Limited (Seqirus) Recent Developments
11.6 AstraZeneca (MedImmune)
11.6.1 AstraZeneca (MedImmune) Corporation Information
11.6.2 AstraZeneca (MedImmune) Business Overview
11.6.3 AstraZeneca (MedImmune) Vaccines For Children Product Models, Descriptions and Specifications
11.6.4 AstraZeneca (MedImmune) Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 AstraZeneca (MedImmune) Recent Developments
11.7 China National Biotec Group
11.7.1 China National Biotec Group Corporation Information
11.7.2 China National Biotec Group Business Overview
11.7.3 China National Biotec Group Vaccines For Children Product Models, Descriptions and Specifications
11.7.4 China National Biotec Group Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 China National Biotec Group Recent Developments
11.8 Hualan Biological Engineering
11.8.1 Hualan Biological Engineering Corporation Information
11.8.2 Hualan Biological Engineering Business Overview
11.8.3 Hualan Biological Engineering Vaccines For Children Product Models, Descriptions and Specifications
11.8.4 Hualan Biological Engineering Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Hualan Biological Engineering Recent Developments
11.9 Shenzhen Kangtai Biological Products
11.9.1 Shenzhen Kangtai Biological Products Corporation Information
11.9.2 Shenzhen Kangtai Biological Products Business Overview
11.9.3 Shenzhen Kangtai Biological Products Vaccines For Children Product Models, Descriptions and Specifications
11.9.4 Shenzhen Kangtai Biological Products Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Shenzhen Kangtai Biological Products Recent Developments
11.10 AIM Vaccine (Hissen)
11.10.1 AIM Vaccine (Hissen) Corporation Information
11.10.2 AIM Vaccine (Hissen) Business Overview
11.10.3 AIM Vaccine (Hissen) Vaccines For Children Product Models, Descriptions and Specifications
11.10.4 AIM Vaccine (Hissen) Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 AIM Vaccine (Hissen) Recent Developments
11.11 Serum Institute of India
11.11.1 Serum Institute of India Corporation Information
11.11.2 Serum Institute of India Business Overview
11.11.3 Serum Institute of India Vaccines For Children Product Models, Descriptions and Specifications
11.11.4 Serum Institute of India Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Serum Institute of India Recent Developments
11.12 Bharat Biotech
11.12.1 Bharat Biotech Corporation Information
11.12.2 Bharat Biotech Business Overview
11.12.3 Bharat Biotech Vaccines For Children Product Models, Descriptions and Specifications
11.12.4 Bharat Biotech Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Bharat Biotech Recent Developments
11.13 Biological E. Limited
11.13.1 Biological E. Limited Corporation Information
11.13.2 Biological E. Limited Business Overview
11.13.3 Biological E. Limited Vaccines For Children Product Models, Descriptions and Specifications
11.13.4 Biological E. Limited Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Biological E. Limited Recent Developments
11.14 Panacea Biotec
11.14.1 Panacea Biotec Corporation Information
11.14.2 Panacea Biotec Business Overview
11.14.3 Panacea Biotec Vaccines For Children Product Models, Descriptions and Specifications
11.14.4 Panacea Biotec Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Panacea Biotec Recent Developments
11.15 Takeda Pharmaceutical
11.15.1 Takeda Pharmaceutical Corporation Information
11.15.2 Takeda Pharmaceutical Business Overview
11.15.3 Takeda Pharmaceutical Vaccines For Children Product Models, Descriptions and Specifications
11.15.4 Takeda Pharmaceutical Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Takeda Pharmaceutical Recent Developments
11.16 KM Biologics
11.16.1 KM Biologics Corporation Information
11.16.2 KM Biologics Business Overview
11.16.3 KM Biologics Vaccines For Children Product Models, Descriptions and Specifications
11.16.4 KM Biologics Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 KM Biologics Recent Developments
11.17 Daiichi Sankyo
11.17.1 Daiichi Sankyo Corporation Information
11.17.2 Daiichi Sankyo Business Overview
11.17.3 Daiichi Sankyo Vaccines For Children Product Models, Descriptions and Specifications
11.17.4 Daiichi Sankyo Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 Daiichi Sankyo Recent Developments
11.18 Sinovac Biotech
11.18.1 Sinovac Biotech Corporation Information
11.18.2 Sinovac Biotech Business Overview
11.18.3 Sinovac Biotech Vaccines For Children Product Models, Descriptions and Specifications
11.18.4 Sinovac Biotech Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Sinovac Biotech Recent Developments
11.19 Walvax Biotechnology
11.19.1 Walvax Biotechnology Corporation Information
11.19.2 Walvax Biotechnology Business Overview
11.19.3 Walvax Biotechnology Vaccines For Children Product Models, Descriptions and Specifications
11.19.4 Walvax Biotechnology Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Walvax Biotechnology Recent Developments
11.20 Beijing Wantai Biological Pharmacy (Innovax)
11.20.1 Beijing Wantai Biological Pharmacy (Innovax) Corporation Information
11.20.2 Beijing Wantai Biological Pharmacy (Innovax) Business Overview
11.20.3 Beijing Wantai Biological Pharmacy (Innovax) Vaccines For Children Product Models, Descriptions and Specifications
11.20.4 Beijing Wantai Biological Pharmacy (Innovax) Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Beijing Wantai Biological Pharmacy (Innovax) Recent Developments
11.21 Zhifei Biological
11.21.1 Zhifei Biological Corporation Information
11.21.2 Zhifei Biological Business Overview
11.21.3 Zhifei Biological Vaccines For Children Product Models, Descriptions and Specifications
11.21.4 Zhifei Biological Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 Zhifei Biological Recent Developments
11.22 CanSino Biologics
11.22.1 CanSino Biologics Corporation Information
11.22.2 CanSino Biologics Business Overview
11.22.3 CanSino Biologics Vaccines For Children Product Models, Descriptions and Specifications
11.22.4 CanSino Biologics Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 CanSino Biologics Recent Developments
11.23 Changchun High-Tech Industries
11.23.1 Changchun High-Tech Industries Corporation Information
11.23.2 Changchun High-Tech Industries Business Overview
11.23.3 Changchun High-Tech Industries Vaccines For Children Product Models, Descriptions and Specifications
11.23.4 Changchun High-Tech Industries Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Changchun High-Tech Industries Recent Developments
11.24 Chengda Biotechnology
11.24.1 Chengda Biotechnology Corporation Information
11.24.2 Chengda Biotechnology Business Overview
11.24.3 Chengda Biotechnology Vaccines For Children Product Models, Descriptions and Specifications
11.24.4 Chengda Biotechnology Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 Chengda Biotechnology Recent Developments
11.25 Denka Company Limited
11.25.1 Denka Company Limited Corporation Information
11.25.2 Denka Company Limited Business Overview
11.25.3 Denka Company Limited Vaccines For Children Product Models, Descriptions and Specifications
11.25.4 Denka Company Limited Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 Denka Company Limited Recent Developments
11.26 SK bioscience
11.26.1 SK bioscience Corporation Information
11.26.2 SK bioscience Business Overview
11.26.3 SK bioscience Vaccines For Children Product Models, Descriptions and Specifications
11.26.4 SK bioscience Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 SK bioscience Recent Developments
11.27 GC Biopharma
11.27.1 GC Biopharma Corporation Information
11.27.2 GC Biopharma Business Overview
11.27.3 GC Biopharma Vaccines For Children Product Models, Descriptions and Specifications
11.27.4 GC Biopharma Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.27.5 GC Biopharma Recent Developments
11.28 LG Chem
11.28.1 LG Chem Corporation Information
11.28.2 LG Chem Business Overview
11.28.3 LG Chem Vaccines For Children Product Models, Descriptions and Specifications
11.28.4 LG Chem Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.28.5 LG Chem Recent Developments
11.29 Bio Farma
11.29.1 Bio Farma Corporation Information
11.29.2 Bio Farma Business Overview
11.29.3 Bio Farma Vaccines For Children Product Models, Descriptions and Specifications
11.29.4 Bio Farma Vaccines For Children Sales, Price, Revenue and Gross Margin (2021-2026)
11.29.5 Bio Farma Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Vaccines For Children Industry Chain
12.2 Vaccines For Children Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Vaccines For Children Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Vaccines For Children Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Vaccines For Children Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Vaccines For Children Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Vaccines For Children Market Size Growth Rate by Vaccine Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Vaccines For Children Market Size Growth Rate by Number of Target Diseases, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Vaccines For Children Market Size Growth Rate by Recommended Age Group, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Vaccines For Children Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Vaccines For Children Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Vaccines For Children Revenue by Region (US$ Million), 2021-2026
Table 7. Global Vaccines For Children Revenue by Region (US$ Million), 2027-2032
Table 8. Global Vaccines For Children Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Table 9. Global Vaccines For Children Sales by Region (K Dose), 2021-2026
Table 10. Global Vaccines For Children Sales by Region (K Dose), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Vaccines For Children Sales by Manufacturers (K Dose), 2021-2026
Table 13. Global Vaccines For Children Sales Share by Manufacturers (2021-2026)
Table 14. Global Vaccines For Children Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Vaccines For Children Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Vaccines For Children Revenue, 2025
Table 18. Global Vaccines For Children Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Vaccines For Children Average Selling Price (ASP) by Manufacturers (US$/Dose), 2021-2026
Table 20. Key Manufacturers Vaccines For Children Manufacturing Base and Headquarters
Table 21. Global Vaccines For Children Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Vaccines For Children Sales Volume by Vaccine Type (K Dose), 2021-2026
Table 25. Global Vaccines For Children Sales Volume by Vaccine Type (K Dose), 2027-2032
Table 26. Global Vaccines For Children Revenue by Vaccine Type (US$ Million), 2021-2026
Table 27. Global Vaccines For Children Revenue by Vaccine Type (US$ Million), 2027-2032
Table 28. Global Vaccines For Children Sales Volume by Number of Target Diseases (K Dose), 2021-2026
Table 29. Global Vaccines For Children Sales Volume by Number of Target Diseases (K Dose), 2027-2032
Table 30. Global Vaccines For Children Revenue by Number of Target Diseases (US$ Million), 2021-2026
Table 31. Global Vaccines For Children Revenue by Number of Target Diseases (US$ Million), 2027-2032
Table 32. Global Vaccines For Children Sales Volume by Recommended Age Group (K Dose), 2021-2026
Table 33. Global Vaccines For Children Sales Volume by Recommended Age Group (K Dose), 2027-2032
Table 34. Global Vaccines For Children Revenue by Recommended Age Group (US$ Million), 2021-2026
Table 35. Global Vaccines For Children Revenue by Recommended Age Group (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Vaccines For Children Sales by Application (K Dose), 2021-2026
Table 38. Global Vaccines For Children Sales by Application (K Dose), 2027-2032
Table 39. Vaccines For Children High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Vaccines For Children Revenue by Application (US$ Million), 2021-2026
Table 41. Global Vaccines For Children Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Vaccines For Children Growth Accelerators and Market Barriers
Table 45. North America Vaccines For Children Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Vaccines For Children Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Vaccines For Children Growth Accelerators and Market Barriers
Table 48. Europe Vaccines For Children Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Vaccines For Children Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Vaccines For Children Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Vaccines For Children Sales (K Dose) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Vaccines For Children Growth Accelerators and Market Barriers
Table 53. Southeast Asia Vaccines For Children Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Vaccines For Children Investment Opportunities and Key Challenges
Table 55. Central and South America Vaccines For Children Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Vaccines For Children Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Vaccines For Children Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. GSK Corporation Information
Table 59. GSK Description and Major Businesses
Table 60. GSK Product Models, Descriptions and Specifications
Table 61. GSK Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 62. GSK Sales Value Proportion by Product in 2025
Table 63. GSK Sales Value Proportion by Application in 2025
Table 64. GSK Sales Value Proportion by Geographic Area in 2025
Table 65. GSK Vaccines For Children SWOT Analysis
Table 66. GSK Recent Developments
Table 67. Sanofi Corporation Information
Table 68. Sanofi Description and Major Businesses
Table 69. Sanofi Product Models, Descriptions and Specifications
Table 70. Sanofi Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 71. Sanofi Sales Value Proportion by Product in 2025
Table 72. Sanofi Sales Value Proportion by Application in 2025
Table 73. Sanofi Sales Value Proportion by Geographic Area in 2025
Table 74. Sanofi Vaccines For Children SWOT Analysis
Table 75. Sanofi Recent Developments
Table 76. Merck & Co. (MSD) Corporation Information
Table 77. Merck & Co. (MSD) Description and Major Businesses
Table 78. Merck & Co. (MSD) Product Models, Descriptions and Specifications
Table 79. Merck & Co. (MSD) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 80. Merck & Co. (MSD) Sales Value Proportion by Product in 2025
Table 81. Merck & Co. (MSD) Sales Value Proportion by Application in 2025
Table 82. Merck & Co. (MSD) Sales Value Proportion by Geographic Area in 2025
Table 83. Merck & Co. (MSD) Vaccines For Children SWOT Analysis
Table 84. Merck & Co. (MSD) Recent Developments
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Major Businesses
Table 87. Pfizer Product Models, Descriptions and Specifications
Table 88. Pfizer Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 89. Pfizer Sales Value Proportion by Product in 2025
Table 90. Pfizer Sales Value Proportion by Application in 2025
Table 91. Pfizer Sales Value Proportion by Geographic Area in 2025
Table 92. Pfizer Vaccines For Children SWOT Analysis
Table 93. Pfizer Recent Developments
Table 94. CSL Limited (Seqirus) Corporation Information
Table 95. CSL Limited (Seqirus) Description and Major Businesses
Table 96. CSL Limited (Seqirus) Product Models, Descriptions and Specifications
Table 97. CSL Limited (Seqirus) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 98. CSL Limited (Seqirus) Sales Value Proportion by Product in 2025
Table 99. CSL Limited (Seqirus) Sales Value Proportion by Application in 2025
Table 100. CSL Limited (Seqirus) Sales Value Proportion by Geographic Area in 2025
Table 101. CSL Limited (Seqirus) Vaccines For Children SWOT Analysis
Table 102. CSL Limited (Seqirus) Recent Developments
Table 103. AstraZeneca (MedImmune) Corporation Information
Table 104. AstraZeneca (MedImmune) Description and Major Businesses
Table 105. AstraZeneca (MedImmune) Product Models, Descriptions and Specifications
Table 106. AstraZeneca (MedImmune) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 107. AstraZeneca (MedImmune) Recent Developments
Table 108. China National Biotec Group Corporation Information
Table 109. China National Biotec Group Description and Major Businesses
Table 110. China National Biotec Group Product Models, Descriptions and Specifications
Table 111. China National Biotec Group Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 112. China National Biotec Group Recent Developments
Table 113. Hualan Biological Engineering Corporation Information
Table 114. Hualan Biological Engineering Description and Major Businesses
Table 115. Hualan Biological Engineering Product Models, Descriptions and Specifications
Table 116. Hualan Biological Engineering Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 117. Hualan Biological Engineering Recent Developments
Table 118. Shenzhen Kangtai Biological Products Corporation Information
Table 119. Shenzhen Kangtai Biological Products Description and Major Businesses
Table 120. Shenzhen Kangtai Biological Products Product Models, Descriptions and Specifications
Table 121. Shenzhen Kangtai Biological Products Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 122. Shenzhen Kangtai Biological Products Recent Developments
Table 123. AIM Vaccine (Hissen) Corporation Information
Table 124. AIM Vaccine (Hissen) Description and Major Businesses
Table 125. AIM Vaccine (Hissen) Product Models, Descriptions and Specifications
Table 126. AIM Vaccine (Hissen) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 127. AIM Vaccine (Hissen) Recent Developments
Table 128. Serum Institute of India Corporation Information
Table 129. Serum Institute of India Description and Major Businesses
Table 130. Serum Institute of India Product Models, Descriptions and Specifications
Table 131. Serum Institute of India Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 132. Serum Institute of India Recent Developments
Table 133. Bharat Biotech Corporation Information
Table 134. Bharat Biotech Description and Major Businesses
Table 135. Bharat Biotech Product Models, Descriptions and Specifications
Table 136. Bharat Biotech Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 137. Bharat Biotech Recent Developments
Table 138. Biological E. Limited Corporation Information
Table 139. Biological E. Limited Description and Major Businesses
Table 140. Biological E. Limited Product Models, Descriptions and Specifications
Table 141. Biological E. Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 142. Biological E. Limited Recent Developments
Table 143. Panacea Biotec Corporation Information
Table 144. Panacea Biotec Description and Major Businesses
Table 145. Panacea Biotec Product Models, Descriptions and Specifications
Table 146. Panacea Biotec Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 147. Panacea Biotec Recent Developments
Table 148. Takeda Pharmaceutical Corporation Information
Table 149. Takeda Pharmaceutical Description and Major Businesses
Table 150. Takeda Pharmaceutical Product Models, Descriptions and Specifications
Table 151. Takeda Pharmaceutical Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 152. Takeda Pharmaceutical Recent Developments
Table 153. KM Biologics Corporation Information
Table 154. KM Biologics Description and Major Businesses
Table 155. KM Biologics Product Models, Descriptions and Specifications
Table 156. KM Biologics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 157. KM Biologics Recent Developments
Table 158. Daiichi Sankyo Corporation Information
Table 159. Daiichi Sankyo Description and Major Businesses
Table 160. Daiichi Sankyo Product Models, Descriptions and Specifications
Table 161. Daiichi Sankyo Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 162. Daiichi Sankyo Recent Developments
Table 163. Sinovac Biotech Corporation Information
Table 164. Sinovac Biotech Description and Major Businesses
Table 165. Sinovac Biotech Product Models, Descriptions and Specifications
Table 166. Sinovac Biotech Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 167. Sinovac Biotech Recent Developments
Table 168. Walvax Biotechnology Corporation Information
Table 169. Walvax Biotechnology Description and Major Businesses
Table 170. Walvax Biotechnology Product Models, Descriptions and Specifications
Table 171. Walvax Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 172. Walvax Biotechnology Recent Developments
Table 173. Beijing Wantai Biological Pharmacy (Innovax) Corporation Information
Table 174. Beijing Wantai Biological Pharmacy (Innovax) Description and Major Businesses
Table 175. Beijing Wantai Biological Pharmacy (Innovax) Product Models, Descriptions and Specifications
Table 176. Beijing Wantai Biological Pharmacy (Innovax) Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 177. Beijing Wantai Biological Pharmacy (Innovax) Recent Developments
Table 178. Zhifei Biological Corporation Information
Table 179. Zhifei Biological Description and Major Businesses
Table 180. Zhifei Biological Product Models, Descriptions and Specifications
Table 181. Zhifei Biological Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 182. Zhifei Biological Recent Developments
Table 183. CanSino Biologics Corporation Information
Table 184. CanSino Biologics Description and Major Businesses
Table 185. CanSino Biologics Product Models, Descriptions and Specifications
Table 186. CanSino Biologics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 187. CanSino Biologics Recent Developments
Table 188. Changchun High-Tech Industries Corporation Information
Table 189. Changchun High-Tech Industries Description and Major Businesses
Table 190. Changchun High-Tech Industries Product Models, Descriptions and Specifications
Table 191. Changchun High-Tech Industries Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 192. Changchun High-Tech Industries Recent Developments
Table 193. Chengda Biotechnology Corporation Information
Table 194. Chengda Biotechnology Description and Major Businesses
Table 195. Chengda Biotechnology Product Models, Descriptions and Specifications
Table 196. Chengda Biotechnology Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 197. Chengda Biotechnology Recent Developments
Table 198. Denka Company Limited Corporation Information
Table 199. Denka Company Limited Description and Major Businesses
Table 200. Denka Company Limited Product Models, Descriptions and Specifications
Table 201. Denka Company Limited Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 202. Denka Company Limited Recent Developments
Table 203. SK bioscience Corporation Information
Table 204. SK bioscience Description and Major Businesses
Table 205. SK bioscience Product Models, Descriptions and Specifications
Table 206. SK bioscience Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 207. SK bioscience Recent Developments
Table 208. GC Biopharma Corporation Information
Table 209. GC Biopharma Description and Major Businesses
Table 210. GC Biopharma Product Models, Descriptions and Specifications
Table 211. GC Biopharma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 212. GC Biopharma Recent Developments
Table 213. LG Chem Corporation Information
Table 214. LG Chem Description and Major Businesses
Table 215. LG Chem Product Models, Descriptions and Specifications
Table 216. LG Chem Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 217. LG Chem Recent Developments
Table 218. Bio Farma Corporation Information
Table 219. Bio Farma Description and Major Businesses
Table 220. Bio Farma Product Models, Descriptions and Specifications
Table 221. Bio Farma Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 222. Bio Farma Recent Developments
Table 223. Key Raw Materials Distribution
Table 224. Raw Materials Key Suppliers
Table 225. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 226. Milestones in Production Technology Evolution
Table 227. Distributors List
Table 228. Market Trends and Market Evolution
Table 229. Market Drivers and Opportunities
Table 230. Market Challenges, Risks, and Restraints
Table 231. Research Programs/Design for This Report
Table 232. Key Data Information from Secondary Sources
Table 233. Key Data Information from Primary Sources

List of Figures
Figure 1. Vaccines For Children Product Picture
Figure 2. Global Vaccines For Children Market Size Growth Rate by Vaccine Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Live Attenuated Vaccines Product Picture
Figure 4. Inactivated Vaccines Product Picture
Figure 5. Subunit and Recombinant Vaccines Product Picture
Figure 6. Conjugate Vaccines Product Picture
Figure 7. Toxoid Vaccines Product Picture
Figure 8. Nucleic Acid Vaccines Product Picture
Figure 9. Others Product Picture
Figure 10. Global Vaccines For Children Market Size Growth Rate by Number of Target Diseases, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Monovalent Vaccines (1 Disease) Product Picture
Figure 12. Bivalent and Trivalent Vaccines (2–3 Diseases) Product Picture
Figure 13. Multivalent Vaccines (≥4 Diseases) Product Picture
Figure 14. Global Vaccines For Children Market Size Growth Rate by Recommended Age Group, 2021 vs 2025 vs 2032 (US$ Million)
Figure 15. Infant Vaccines (0–12 Months) Product Picture
Figure 16. Toddler Vaccines (>12–36 Months) Product Picture
Figure 17. Childhood Vaccines (>3–12 Years) Product Picture
Figure 18. Adolescent Vaccines (>12–17 Years) Product Picture
Figure 19. Global Vaccines For Children Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 20. Hospitals
Figure 21. Community Health Centers
Figure 22. Vaccination Clinics
Figure 23. Others
Figure 24. Vaccines For Children Report Years Considered
Figure 25. Global Vaccines For Children Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 26. Global Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 27. Global Vaccines For Children Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 28. Global Vaccines For Children Revenue-Based Market Share by Region (2021-2032)
Figure 29. Global Vaccines For Children Sales (K Dose), 2021-2032
Figure 30. Global Vaccines For Children Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Dose)
Figure 31. Global Vaccines For Children Sales Market Share by Region (2021-2032)
Figure 32. Top 5 and Top 10 Manufacturers Vaccines For Children Sales Volume Market Share in 2025
Figure 33. Global Vaccines For Children Revenue-Based Market Share Ranking (2025)
Figure 34. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 35. Live Attenuated Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 36. Inactivated Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 37. Subunit and Recombinant Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 38. Conjugate Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 39. Toxoid Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 40. Nucleic Acid Vaccines Revenue-Based Market Share by Manufacturer in 2025
Figure 41. Others Revenue-Based Market Share by Manufacturer in 2025
Figure 42. Global Vaccines For Children Sales Volume-Based Market Share by Vaccine Type (2021-2032)
Figure 43. Global Vaccines For Children Revenue-Based Market Share by Vaccine Type (2021-2032)
Figure 44. Global Vaccines For Children ASP by Vaccine Type (US$/Dose), 2021-2032
Figure 45. Global Vaccines For Children Sales Volume-Based Market Share by Number of Target Diseases (2021-2032)
Figure 46. Global Vaccines For Children Revenue-Based Market Share by Number of Target Diseases (2021-2032)
Figure 47. Global Vaccines For Children ASP by Number of Target Diseases (US$/Dose), 2021-2032
Figure 48. Global Vaccines For Children Sales Volume-Based Market Share by Recommended Age Group (2021-2032)
Figure 49. Global Vaccines For Children Revenue-Based Market Share by Recommended Age Group (2021-2032)
Figure 50. Global Vaccines For Children ASP by Recommended Age Group (US$/Dose), 2021-2032
Figure 51. Global Vaccines For Children Sales Market Share by Application (2021-2032)
Figure 52. Global Vaccines For Children Revenue-Based Market Share by Application (2021-2032)
Figure 53. Global Vaccines For Children ASP by Application (US$/Dose), 2021-2032
Figure 54. North America Vaccines For Children Sales YoY (K Dose), 2021-2032
Figure 55. North America Vaccines For Children Revenue YoY (US$ Million), 2021-2032
Figure 56. North America Top 5 Manufacturers Vaccines For Children Sales Revenue (US$ Million) in 2025
Figure 57. North America Vaccines For Children Sales Volume (K Dose) by Application (2021-2032)
Figure 58. North America Vaccines For Children Sales Revenue (US$ Million) by Application (2021-2032)
Figure 59. US Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 60. Canada Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 61. Mexico Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 62. Europe Vaccines For Children Sales YoY (K Dose), 2021-2032
Figure 63. Europe Vaccines For Children Revenue YoY (US$ Million), 2021-2032
Figure 64. Europe Top 5 Manufacturers Vaccines For Children Sales Revenue (US$ Million) in 2025
Figure 65. Europe Vaccines For Children Sales Volume (K Dose) by Application (2021-2032)
Figure 66. Europe Vaccines For Children Sales Revenue (US$ Million) by Application (2021-2032)
Figure 67. Germany Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 68. France Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 69. U.K. Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 70. Italy Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 71. Russia Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 72. Asia-Pacific Vaccines For Children Sales YoY (K Dose), 2021-2032
Figure 73. Asia-Pacific Vaccines For Children Revenue YoY (US$ Million), 2021-2032
Figure 74. Asia-Pacific Top 8 Manufacturers Vaccines For Children Sales Revenue (US$ Million) in 2025
Figure 75. Asia-Pacific Vaccines For Children Sales Volume (K Dose) by Application (2021-2032)
Figure 76. Asia-Pacific Vaccines For Children Sales Revenue (US$ Million) by Application (2021-2032)
Figure 77. Indonesia Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 78. Japan Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 79. South Korea Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 80. China Taiwan Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 81. India Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 82. Central and South America Vaccines For Children Sales YoY (K Dose), 2021-2032
Figure 83. Central and South America Vaccines For Children Revenue YoY (US$ Million), 2021-2032
Figure 84. Central and South America Top 5 Manufacturers Vaccines For Children Sales Revenue (US$ Million) in 2025
Figure 85. Central and South America Vaccines For Children Sales Volume (K Dose) by Application (2021-2032)
Figure 86. Central and South America Vaccines For Children Sales Revenue (US$ Million) by Application (2021-2032)
Figure 87. Brazil Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 88. Argentina Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 89. Middle East, and Africa Vaccines For Children Sales YoY (K Dose), 2021-2032
Figure 90. Middle East and Africa Vaccines For Children Revenue YoY (US$ Million), 2021-2032
Figure 91. Middle East and Africa Top 5 Manufacturers Vaccines For Children Sales Revenue (US$ Million) in 2025
Figure 92. Middle East and Africa Vaccines For Children Sales Volume (K Dose) by Application (2021-2032)
Figure 93. Middle East and Africa Vaccines For Children Sales Revenue (US$ Million) by Application (2021-2032)
Figure 94. GCC Countries Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 95. Turkey Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 96. Egypt Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 97. South Africa Vaccines For Children Revenue (US$ Million), 2021-2032
Figure 98. Vaccines For Children Industry Chain Mapping
Figure 99. Regional Vaccines For Children Manufacturing Base Distribution (%)
Figure 100. Global Vaccines For Children Production Market Share by Region (2021-2032)
Figure 101. Vaccines For Children Production Process
Figure 102. Regional Vaccines For Children Production Cost Structure
Figure 103. Channels of Distribution (Direct Vs Distribution)
Figure 104. Bottom-up and Top-down Approaches for This Report
Figure 105. Data Triangulation
Figure 106. Key Executives Interviewed